Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 640 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer September 14, 2022 Help Desk for Oncologists Treating People with a Rare Leukemia Pays... February 2, 2023 New on NCI’s Websites for April 2024 April 12, 2024 Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies June 16, 2021 Load more HOT NEWS FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Paediatric Patients... Epigenetic Changes Pinpointed as the Cause of Some GISTs Ensuring a Smooth Leadership Transition at NCI Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk...
